Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma (NCT06375044)
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Mayo Clinic Arizona — Phoenix, Arizona
- UC Irvine Health — Orange, California
- Mayo Clinic Florida — Jacksonville, Florida
- Dana Farber Cancer institution — Boston, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute — New York, New York
- University of North Carolina Hospitals at Hillsborough — Hillsborough, North Carolina
- Tennessee Oncology — Nashville, Tennessee
- Beijing Chaoyang Hospital Capital Medical University — Beijing, Beijing Municipality
- The First Affiliated Hospital of FuJian Medical University — Fuzhou, Fujian
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong
- Henan Cancer Hospital — Zhengzhou, Henan
- Nanjing Drum Tower Hospital — Nanjing, Jiangsu
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences — Tianjin, Tianjin Municipality
- The First Affiliated Hospital Zhejiang University School of Medicine — Hanzhou, Zhejiang
📞 Contact the Study Coordinator
Phone: (857) 333-0740
Email: clinicaltrials@simceregroup.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed or Refractory Multiple Myeloma
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) — Mobile, Alabama
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma — Anchorage, Alaska
- A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma — Toronto, Ontario
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma — Tucson, Arizona
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
- A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Relapsed or Refractory Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.